德琪医药-B(06996)：ATG-022联合KEYTRUDA®(帕博利珠单抗)±化疗的IB/II期研究于中国获授予IND批准

Core Viewpoint - The approval of the investigational new drug (IND) application for ATG-022, a CLDN18.2 antibody-drug conjugate, in combination with MSD's KEYTRUDA® and chemotherapy, marks a significant advancement in cancer treatment research [1] Group 1: Company Developments - The China National Medical Products Administration (NMPA) has approved the IND application for ATG-022 in conjunction with KEYTRUDA® and chemotherapy [1] - The clinical study, named CLINCH-2, is an Ib/II phase trial aimed at evaluating the efficacy of the combination therapy [1]